Concordance Between ctDNA Assay and FoundationOne

Completed

Conditions studied: Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing, Genomic Alterations

In brief

Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has been developing an assay in order to do so.

Key facts

Study ID

NCT02620527

Run by

Foundation Medicine

People needed

1400

Starts

2014-11-01

Expected to finish

2017-12-01

Last updated by the study team

2018-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have had a solid tumor biopsy isolated for analysis by FoundationOne under their standard clinical care

You may not qualify if…

• Tumor specimens where no cancer representative of the diagnosis is found in submitted tissue
• Tumor specimens where insufficient DNA (<50 ng) is provided to run the FoundationOne test.
• Tumor specimens with ≤20% tumor nuclei (all specimens).

Where it is running

• Foundation Medicine — Cambridge, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.